

# PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP7178a

# **Specification**

# PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - Product Information

Primary Accession P60891
Other Accession O5JV75

# PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - Additional Information

## **Gene ID** 5631

# **Other Names**

Ribose-phosphate pyrophosphokinase 1, PPRibP, Phosphoribosyl pyrophosphate synthase I, PRS-I, PRPS1

# **Target/Specificity**

The synthetic peptide sequence used to generate the antibody <a

href=/product/products/AP7178a>AP7178a</a> was selected from the C-term region of human PRPS1/2/3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

## **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - Protein Information

# Name PRPS1 (HGNC:9462)

## **Function**

Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis.

## PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides





# PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - Images PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - Background

Phosphoribosylpyrophosphate synthetase (PRPS) catalyzes the phosphoribosylation of ribose 5-phosphate to 5-phosphoribosyl-1-pyrophosphate, which is necessary for the de novo and salvage pathways of purine, pyrimidine, and pyridine biosynthesis. Defects in PRPS1 are the cause of PRPS-related gout, also known as gout due to PRPS1 superactivity. It is a familial disorder characterized by excessive purine production, gout and uric acid urolithiasis.

# PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide - References

Ahmed, M., et al., J. Biol. Chem. 274(11):7482-7488 (1999).lshijima, S., et al., Biochim. Biophys. Acta 1342(1):28-36 (1997). Becker, M.A., et al., J. Biol. Chem. 271(33):19894-19899 (1996). Roessler, B.J., et al., J. Biol. Chem. 268(35):26476-26481 (1993). Ishizuka, T., et al., Biochim. Biophys. Acta 1130(2):139-148 (1992).